Phase 3 human clinical trial shows that metabolic activators accelerate recovery in COVID-19 patients
The Swedish biotechnology company ScandiBio Therapeutics today announced results from the study. The study conducted in Turkey was published on February 20 on medRxiv, a preprint publication website. The study was conducted in partnership with California-based ChromaDex (NASDAQ:CDXC) that provided one of the four ingredients (nicotinamide riboside) through the ChromaDex External Research Program (CERP).
The study: Combined Metabolic Activators accelerates recovery in mild-to-moderate COVID-19
The human phase 3 clinical study demonstrated that patients with mild-to-moderate COVID-19 receiving standard of care experienced a 3.5 day reduction in recovery time when receiving the activators. Aimed at improving mitochondrial function, the protocol included nicotinamide riboside (NR), L-serine, N-acetyl-L-cysteine (NAC), and L-carnitine tartrate. The results of the study build on findings from Phase 2 clinical data published in October 2020. The addition of the metabolic activators to the standard of care not only reduced recovery time, but improved liver health and decreased levels of inflammatory markers as shown in the publication.
